Wegovy 7.2 mg FDA Approval: What the Higher Dose Semaglutide Means for Weight Loss Treatment in

Who Is Most Likely to Benefit from Escalation to 7.2 mg?

Not every patient taking Wegovy will need or benefit from the 7.2 mg dose. Clinical trial subgroup analyses indicate that the incremental weight reduction between 2.4 mg and 7.2 mg was most clinically significant among participants with a baseline BMI above 35 and those with insulin resistance or prediabetes. For these individuals, the higher semaglutide exposure appears to overcome a degree of GLP-1 receptor desensitization that can develop over months of treatment, restoring appetite suppression and gastric emptying effects that may have diminished.

Prescribers evaluating whether to escalate should consider several practical factors. Patients who lost less than 10% of their baseline body weight after 12 months on 2.4 mg — despite adherence to dietary and physical activity recommendations — represent the clearest candidates. Conversely, individuals who achieved satisfactory weight reduction at lower doses gain little from escalation and face unnecessary exposure to dose-dependent side effects. The prescribing information emphasizes shared decision-making, encouraging clinicians to discuss realistic outcome expectations with patients before increasing the dose. Gastroenterologists have also weighed in, noting that patients with a history of gastroparesis or severe gastroesophageal reflux disease should be evaluated carefully, as higher semaglutide doses further slow gastric motility.

What Happens When Patients Stop Taking the 7.2 mg Dose?

One of the most pressing clinical questions surrounding high-dose semaglutide is what happens after cessation. Data from the STEP 1 trial extension showed that participants who discontinued semaglutide 2.4 mg regained approximately two-thirds of their lost weight within one year. While dedicated discontinuation data for the 7.2 mg dose are still being collected, pharmacological principles suggest a similar trajectory — appetite-regulating hormones revert toward pre-treatment levels once GLP-1 receptor stimulation ceases, and compensatory increases in hunger drive weight regain.

This reality has prompted obesity medicine specialists to frame Wegovy — at any dose — as a long-term or indefinite therapy for most patients, comparable to antihypertensive or lipid-lowering medications. The framing carries significant implications for healthcare costs and patient expectations. Some patients may assume that achieving a target weight allows them to discontinue the medication, only to experience frustrating regain. Clinicians are increasingly incorporating pre-treatment counseling about the chronic treatment model into their practice, setting expectations that dose reduction rather than complete cessation may be a more sustainable approach for patients who wish to lower their medication burden.

How Does the 7.2 mg Approval Affect Prescription Patterns and Drug Supply?

The semaglutide supply chain disruptions of 2023–2024 left lasting impressions on patients and providers alike. During peak shortage periods, patients on stable Wegovy doses faced interruptions that forced temporary dose reductions or treatment pauses, undermining adherence and clinical outcomes. With the 7.2 mg approval expanding the per-patient dose requirement by up to threefold compared to the 2.4 mg maintenance dose, industry analysts have questioned whether manufacturing capacity can keep pace with demand.

Novo Nordisk has publicly stated that it invested over $6 billion in manufacturing expansion between 2023 and 2025, including new fill-finish facilities in Denmark and the United States. The company projects that supply constraints for semaglutide products will be largely resolved by late 2026. However, pharmacy benefit managers and specialty pharmacies have signaled that they may implement step-therapy protocols requiring documented inadequate response at 2.4 mg before authorizing the higher dose, both as a cost-containment measure and to moderate demand growth. These administrative requirements could create delays for patients who need dose escalation, and advocacy groups have urged insurers to streamline prior authorization processes for the 7.2 mg tier.